BeOne Medicines (ONC) Notes Payables (2017 - 2025)

BeOne Medicines (ONC) posted quarterly Notes Payables of $813.3 million for Q3 2025, down 4.49% quarter-over-quarter from $851.5 million in Q4 2024.

Analysis

BeOne Medicines (ONC) Notes Payables (2017 - 2025) Analysis & Trends

BeOne Medicines (ONC) has reported Notes Payables for 4 consecutive years, with $813.3 million the latest figure, recorded in Q3 2025.

In Q3 2025, Notes Payables changed N/A year-over-year to $813.3 million; the TTM figure through Sep 2025 stood at $813.3 million (changed N/A YoY), while the FY2024 annual figure was $851.5 million, changed N/A from the prior year.
Notes Payables declined to $813.3 million in Q3 2025 per ONC's latest filing, from $851.5 million in the prior quarter.
Across five years, Notes Payables topped out at $851.5 million in Q4 2024 and bottomed at $813.3 million in Q3 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Incyte	25.44 Bn	20.91 Bn	1.57 Bn

Historic Data

Download Data